# A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

> **NCT06481306** · PHASE1,PHASE2 · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 184 (estimated)

## Conditions studied

- Anemia, Sickle Cell
- Healthy Volunteers

## Interventions

- **DRUG:** BMS-986470
- **DRUG:** Placebo
- **DRUG:** Famotidine

## Key facts

- **NCT ID:** NCT06481306
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-17
- **Primary completion:** 2027-01-06
- **Final completion:** 2027-11-16
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06481306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06481306, "A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease". Retrieved via AI Analytics 2026-08-08 from https://api.ai-analytics.org/clinical/NCT06481306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*